Compare OBDC & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBDC | IMVT |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3B | 5.0B |
| IPO Year | 2015 | 2019 |
| Metric | OBDC | IMVT |
|---|---|---|
| Price | $11.35 | $26.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $14.28 | ★ $30.78 |
| AVG Volume (30 Days) | ★ 5.6M | 1.2M |
| Earning Date | 05-06-2026 | 05-28-2026 |
| Dividend Yield | ★ 13.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.52 | $13.36 |
| 52 Week High | $15.19 | $29.25 |
| Indicator | OBDC | IMVT |
|---|---|---|
| Relative Strength Index (RSI) | 55.50 | 58.64 |
| Support Level | $11.07 | $24.63 |
| Resistance Level | $11.69 | $27.71 |
| Average True Range (ATR) | 0.32 | 1.28 |
| MACD | 0.04 | 0.24 |
| Stochastic Oscillator | 90.76 | 91.94 |
Blue Owl Capital Corp is a specialty finance company and business development company (BDC) focused on providing direct lending solutions to U.S. middle-market companies. The company seeks to generate current income and, to a lesser extent, capital appreciation by targeting investment opportunities with favorable risk-adjusted returns, including senior secured, subordinated, or mezzanine loans and equity-related instruments. Its investment strategies are intended to generate favorable returns across credit cycles with an emphasis on preserving capital.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.